Procalcitonin as a diagnostic marker for infection in sickle cell disease

References

• SCDC program report: data to action. Available from: https://www.cdc.gov/ncbddd/hemoglobinopathies/data-reports/2018-summer/index.html
   Google Scholar
• Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018–2031.
   PubMed Web of Science ®Google Scholar
• Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006 Nov;81(11):858–863.
   PubMed Web of Science ®Google Scholar
• Yawn BP, John-Sowah J. Management of sickle cell disease: recommendations from the 2014 Expert panel report. Am Fam Physician. 2015 Dec 15;92(12):1069–1076.
   PubMedGoogle Scholar
• Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010 Jan 1;159(2):253–264.
   PubMed Web of Science ®Google Scholar
• Becker KL, Nylen ES, White JC, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004 Apr;89(4):1512–1525.
   PubMed Web of Science ®Google Scholar
• Alsayed S, Marzouk S, Mousa E. Serum procalcitonin as a predicting value in severity and prognosis of CAP in sickle cell-patients. J Egypt Soc Parasitol. 2013 Dec;43(3):657–668.
   PubMedGoogle Scholar
• Elenga N, Placide L, Cuadro-Alvarez E, et al. Does procalcitonin predict bacterial infection in febrile children with sickle cell disease? Indian J Pediatr. 2019 Jan;86(1):95–96.
   PubMedGoogle Scholar
• Razazi K, Gendreau S, Cuquemelle E, et al. Procalcitonin to reduce antibiotic exposure during acute chest syndrome in adult patients with sickle-cell disease. J Clin Med. 2020 Nov 19;9(11):3718.
   Google Scholar
• Rincón-López EM, Navarro Gómez ML, Hernández-Sampelayo Matos T, et al. Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer. 2019 Jun;66(6):e27667.
   PubMedGoogle Scholar
• Scott LK, Grier LR, Arnold TC, et al. Serum procalcitonin concentration as a negative predictor of serious bacterial infection in acute sickle cell pain crisis. Med Sci Monit. 2003 Oct;9(10):Cr426–31.
   PubMedGoogle Scholar
• Stankovic Stojanovic K, Steichen O, Lionnet F, et al. Is procalcitonin a marker of invasive bacterial infection in acute sickle-cell vaso-occlusive crisis? Infection. 2011 Feb;39(1):41–45.
   PubMedGoogle Scholar
• Unal S, Arslankoylu AE, Kuyucu N, et al. Procalcitonin is more useful than C-reactive protein in differentiation of fever in patients with sickle cell disease. J Pediatr Hematol Oncol. 2012 Mar;34(2):85–89.
   PubMedGoogle Scholar
• Patel DK, Mohapatra MK, Thomas AG, et al. Procalcitonin as a biomarker of bacterial infection in sickle cell vaso-occlusive crisis. Mediterr J Hematol Infect Dis. 2014;6(1):e2014018.
   PubMedGoogle Scholar
• Lanaro C, Franco-Penteado CF, Albuqueque DM, et al. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2009 Feb;85(2):235–242.
   PubMed Web of Science ®Google Scholar
• Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):195–200.
   PubMedGoogle Scholar
• Sarray S, Saleh LR, Lisa Saldanha F, et al. Serum IL-6, IL-10, and TNFalpha levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine. 2015 Mar;72(1):43–47.
   PubMed Web of Science ®Google Scholar
• Lachant NA, Oseas RS. Vaso-occlusive crisis-associated neutrophil dysfunction in patients with sickle-cell disease. Am J Med Sci. 1987 Oct;294(4):253–257.
   PubMedGoogle Scholar
• Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 1998 Jan 1;91(1):266–274.
   PubMed Web of Science ®Google Scholar
• Hierso R, Lemonne N, Villaescusa R, et al. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study. Br J Haematol. 2017 Mar;176(5):805–813.
   PubMed Web of Science ®Google Scholar
• Müller B, White JC, Nylén ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 Jan;86(1):396–404.
   PubMed Web of Science ®Google Scholar
• Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000 Apr;28(4):977–983.
   PubMed Web of Science ®Google Scholar
• Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515–518.
   PubMed Web of Science ®Google Scholar
• Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017 Jul 15;65(2):183–190.
   PubMed Web of Science ®Google Scholar
• Biemond BJ, Van Tuijn CFJ, Gaartman AE, et al. Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease. Blood. 2018;132(Supplement 1):3660.
   Google Scholar
• Müller B, Prat C. Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. Clin Microbiol Infect. 2006;12(s9):8–16.
   PubMedGoogle Scholar